Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 29 of 29 matching drugs for EPHA5 — including drugs targeting any of its 4 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib EPHA5 Direct 3
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment EPHA5 Direct 2
afatinib, dasatinib, palbociclib, everolimus, olaparib EPHA5 Direct 1
bevacizumab, dasatinib, placebo EPHA5 Direct 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride EPHA5 Direct 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method EPHA5 Direct 1
dasatinib, laboratory biomarker analysis, physiologic testing EPHA5 Direct 1
dasatinib, mfolfox6 EPHA5 Direct 1
dasatinib, pharmacological study EPHA5 Direct 1
dasatinib, temozolomide, placebo, radiation therapy EPHA5 Direct 1
vandetanib EPHA5 Direct yes 0
afatinib EGFR SSL via EGFR yes 2
dacomitinib EGFR SSL via EGFR yes 2
erlotinib EGFR SSL via EGFR yes 2
gefitinib EGFR SSL via EGFR yes 2
lazertinib and amivantamab EGFR SSL via EGFR 1
osimertinib EGFR SSL via EGFR yes 1
afatinib dimaleate EGFR SSL via EGFR yes 0
cetuximab EGFR SSL via EGFR yes 0
erlotinib hydrochloride EGFR SSL via EGFR yes 0
lapatinib EGFR SSL via EGFR yes 0
lapatinib ditosylate EGFR SSL via EGFR yes 0
necitumumab EGFR SSL via EGFR yes 0
neratinib EGFR SSL via EGFR yes 0
neratinib maleate EGFR SSL via EGFR yes 0
osimertinib mesylate EGFR SSL via EGFR yes 0
panitumumab EGFR SSL via EGFR yes 0
regorafenib EGFR SSL via EGFR yes 0
vandetanib EGFR SSL via EGFR yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.